glp 1 ra with cvd benefit The Benefits of GLP-1 Therapy: Beyond Weight Loss The expanding benefits of GLP-1

Park, J.Y

The role of other organelles in ferroptosis is much less studied

Experts to Give Update on GLP-1 RAs and SGLT2i as Adjuncts to Automated Insulin Delivery

placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes